ASSESSMENT OF INDUCED SPUTUM

诱发痰的评估

• 批准号: 7604596
• 负责人: Pamela L. Zeitlin
• 金额: $ 0.05万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604596
• 关键词: Address; Anti-Inflammatory Agents; Anti-inflammatory; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Control Groups; Elastases; Funding; Grant; Ibuprofen; Institution; Measures; Outcome Measure; Pancreatic Elastase; Property; Recovery; Research; Research Personnel; Resources; Saline; Screening procedure; Source; Specimen; Sputum; Testing; United States National Institutes of Health; Upper arm; Week; celecoxib; cystic fibrosis patients; cytokine; neutrophil; treatment duration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory properties is a suitable candidate for more extensive clinical trials in patients with CF. This aim will be addressed using one anti-inflammatory agent, ibuprofen, that has been shown to have clinical benefit in CF, and one anti-inflammatory agent, celecoxib, that has potential to have clinical benefit in CF. A "no treatment" arm will be included as the control group. The outcome measures will be assessed in induced sputum specimens before (Baseline Period), during (Treatment Period), and after (recovery Period) a 4-week treatment period in clinically stable CF patients. Changes will be assessed within each arm and between arms.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 为了确定使用高渗盐水诱导的痰液中测量的中性粒细胞、活性弹性蛋白酶和细胞因子是否是有用的筛选试验，用于确定具有已知抗炎特性的特定药物是否是CF患者更广泛临床试验的合适候选药物。这一目标将通过使用一种抗炎药布洛芬和一种抗炎药塞来昔布来实现，布洛芬已被证明在CF中具有临床获益，塞来昔布有可能在CF中具有临床获益。将纳入“无治疗”组作为对照组。在临床稳定的CF患者中，将在4周治疗期前（基线期）、期间（治疗期）和之后（恢复期）对诱导痰标本进行结局指标评估。将评估每组内和组间的变化。